March 20, 2017 07:31 AM EDT
R&D

Lag­gard Lil­ly says its CDK 4/6 drug abe­maci­clib scored in PhI­II, while ri­vals at No­var­tis, Pfiz­er sharp­en their knives

John Carroll

Editor & Founder

Just a week af­ter No­var­tis scored a key ap­proval for its CDK 4/6 can­cer drug, Eli Lil­ly is an­nounc­ing that its long-await­ed Phase III read­out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

A service from the Financial Times